#United States #Viking Therapeutics #Washington D.C. #VK2735 #ObesityWeek

Viking Therapeutics Presents Key Findings at ObesityWeek 2026

Viking Therapeutics, Inc., a biopharmaceutical company dedicated to developing innovative therapies for metabolic disorders, is making headlines as it showcases two significant poster presentations at the prestigious ObesityWeek® 2026, held from November 14 to 17 in Washington, D.C. This annual meeting attracts prominent stakeholders in the field of obesity treatment and research, providing an excellent platform for Viking to highlight its advancements in obesity therapies.

Overview of Presentations

The two posters focus on vital aspects of the VK2735 program, which is being actively researched as a novel approach for treating obesity and related metabolic disorders. The details of the presentations are as follows:

1. Title: VANQUISH-2 SC VK2735 Study in Adults With Overweight and Type 2 Diabetes: Baseline Characteristics
Presenter: Dr. Jamy Ard, MD, FTO
Track: Diabetes, Weight Management, Sex Specific Outcomes
Date/Time: Saturday, November 14, 2026, from 7:30 PM to 8:30 PM ET
Location: Exhibit Hall BCD, Gaylord National Resort & Convention Center

2. Title: Impact of SC VK2735 on Obesity Severity and Cardiometabolic Parameters in the VENTURE Study
Presenter: Dr. Harold Bays, MD, MFOMA, FTOS, FACC, FNLA, FASPC, DABOM
Track: Clinical Trials Efficacy, Safety, Weight Loss Outcomes
Date/Time: Sunday, November 15, 2026, from 2:30 PM to 3:30 PM ET
Location: Exhibit Hall BCD, Gaylord National Resort & Convention Center

Both presentations aim to provide insights into the mechanisms of VK2735 and its impact on patients suffering from obesity-related health issues, such as type 2 diabetes. The data presented will help to elucidate how VK2735 not only aids in weight loss but also significantly improves cardiometabolic health metrics, which is crucial in the management of obesity.

About VK2735

VK2735 operates as a dual agonist targeting both glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This innovative mechanism is anticipated to yield synergistic effects in managing obesity and its associated conditions. Currently in development for both subcutaneous and oral delivery, VK2735 represents a promising future in the therapeutic landscape of metabolic disorders.

The promising results demonstrated in both the VANQUISH-2 and VENTURE studies highlight Viking's commitment to advancing treatment options that effectively target the complexities of obesity. The company's rigorous scientific approach, combined with deep expertise in metabolic biology, positions it as a leader in the biopharmaceutical field focused on obesity.

Future Directions

The strong focus on VK2735 aligns with Viking's broader objective of delivering impactful interventions for patients grappling with obesity and its related complications. Additionally, Viking is progressing with other obesity treatments, including VK3019, an amylin receptor agonist, and VK2809, aimed at thyroid hormone receptor beta agonism for metabolic and liver diseases. These initiatives underscore the company's dedication to improving patient outcomes and providing comprehensive treatment options.

Conclusion

As Viking Therapeutics shares its research findings at ObesityWeek 2026, the biopharmaceutical company continues to pave the way for innovative solutions in the treatment of obesity and its comorbidities. The results from these studies offer hope for those affected by these challenging conditions and demonstrate Viking's leading role in the advancement of metabolic disease therapies. For ongoing updates and further information about Viking's expanding pipeline, interested individuals can visit Viking Therapeutics.